… for the end of Q3. Inventory days decreased sequentially … 406 million. Net capital expenditures for the third quarter were $80 million. … As Greg detailed, our third-quarter results were very strong, … , diagnostic equipment, and pharma solutions where our PII …

… to close in the third quarter of 2025. The … is expected in the third quarter of 2025. Advisors Moelis … About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical … financial performance and projected expenditures; Supernus’ ability to …

… for the third quarter ended April 26, 2025. Third Quarter Highlights Net … digital sales increased 10% Third Quarter of Fiscal 2025 … remodeled stores, higher pharmacy sales and inflation in … due primarily to capital expenditures. Interest expense decreased in …

… for the third quarter ending March 31, 2025 (" Q3 2025 … The financial results for Q3 2025 have laid a strong … convenience, grocery, drug/pharmacy retail and online. These products … effects of financing and capital expenditures. It is often used …

… the Costco Wholesale Corporation Third Quarter 2025 Conference Call. … Wholesale Corporation’s third quarter 2025 earnings call. … the quarter. Capital expenditure in Q3 was approximately $1 … Within ancillary businesses, pharmacy and optical departments led …

… 31, 2025. “The third quarter of 2025 represents a … were bioavailable, with pharmacokinetic profiles comparable to their … initiatives and reduced overhead expenditures. Research and Development … , or no approved pharmaceutical treatment options. For additional …

… , 2025 (“Q3 FY 2025”). Q3 FY 2025 … Q3 FY 2025, from $13.9 million in the third quarter … new drug or pharmaceutical discoveries; general economic …             Cash Flows From Investing Activities                 Expenditures for property and equipment     (117 …

… for its fiscal 2025 third quarter ended March 31, … We also achieved record third quarter cash generation and increased … beverage, consumer products, and pharmaceutical. The transaction is expected … operating activities less capital expenditures, a non-GAAP …

… 2025 and declared a third-quarter 2025 dividend. First … Directors has approved a third-quarter 2025 dividend of … cash flow minus capital expenditures) was $58.1 … and-declares-third-quarter-2025-dividend-302436657.html SOURCE West Pharmaceutical Services, …

Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”)  Continued momentum with completed patient enrollment for the 6-week interim analysis (n=24) …